Resources Repository
-
ArticlePublication 2020Testing for SARS-CoV-2 Antibodies
Antibody testing can determine previous exposure to SARS-CoV-2 virus. Recently, the UK government has made …
Antibody testing can determine previous exposure to SARS-CoV-2 virus. Recently, the UK government has made antibody testing available to anyone wanting it, even if there is no clinical indication. The purpose of this article is to provide guidance for when to consider antibody testing in individuals with and without symptoms suggestive of current or past SARS-CoV-2 infection. Key points made by the authors include: (1) antibody testing is likely to be most useful 2 weeks…
Probability/Bayes | Technology Assessment | Health/Medicine | Test Performance | Infectious Diseases | Clinical Care -
ArticlePublication 2016Estimating Benefits of Regulations Affecting Addictive Goods
The question of how to evaluate lost consumer surplus in benefit−cost analyses is controversial. There …
The question of how to evaluate lost consumer surplus in benefit−cost analyses is controversial. There are clear health benefits of regulations that curb consumption of goods with health risks, such as tobacco products and foods high in fats, calories, sugar, and sodium. Yet, if regulations cause consumers to give up goods they like, the health benefits they experience may be offset by some utility loss, which benefit−cost analyses of regulations need to take into account.…
Benefit-Cost Analysis | Decision Theory | Health/Medicine | Preferences/Values | Mental Health -
ReviewPublication 2016Using Economic Evidence to Set Healthcare Priorities in LMIC
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks …
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks for identifying priority health interventions. This paper synthesizes and appraises the literature on methodological frameworks – which incorporate economic evaluation evidence – for the purpose of setting healthcare priorities in LMICs. A systematic search of Embase, MEDLINE, Econlit and PubMed identified 3968 articles with a further 21 articles identified through manual searching. A total of 36 papers were eligible for inclusion.…
Technology Assessment | Benefit-Cost Analysis | Health/Medicine | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2007Decision Analysis: A Personal Account of How It Got Started and Evolved
In this chapter, Howard Raiffa discusses the evolution of decision analysis and his personal involvement …
In this chapter, Howard Raiffa discusses the evolution of decision analysis and his personal involvement in its development. He describes the early days of Operations Research (OR) in the late 1940s with its approach to complex, strategic decision making. After reading John von Neumann and Oskar Morgenstern’s Theory of Games and Economic Behavior (1947) and Abraham Wald’s two books (1947, 1950), he became involved in statistical decision theory. A few years later, after reading Leonard…
Probability/Bayes | Decision Theory | Health/Medicine | Preferences/Values | Decision Analysis | Operations Research | Business/Industry | Economics/Finance | Energy/Engineering -
ReviewPublication 2023Adaptive Health Technology Assessment: A Scoping Review of Methods
This study explores adaptive health technology assessment (aHTA) as an expedited alternative to full HTA, …
This study explores adaptive health technology assessment (aHTA) as an expedited alternative to full HTA, aiming to support universal health coverage by leveraging HTA evidence from other settings. The scoping review identified and mapped existing aHTA methods, examining their triggers, strengths, and weaknesses. Methods included searching HTA agencies' and networks' websites, and published literature, with findings narratively synthesized. The review found aHTA methods in 20 countries and one HTA network across the Americas, Europe, Africa,…
Technology Assessment | Health/Medicine | Priority Setting/Ethics | Cost-Effectiveness Analysis | Global -
ReviewPublication 2023Inclusion of Environmental Spillovers in Applied Economic Evaluations of Healthcare Products
This review examines the inclusion of environmental spillovers in economic evaluations of healthcare products and …
This review examines the inclusion of environmental spillovers in economic evaluations of healthcare products and health technology assessments (HTA). Environmental spillovers, such as CO2 emissions, water and energy consumption, and waste disposal, significantly impact human and planetary health but are often excluded from HTAs. The review's objective is to identify economic evaluations and guidelines incorporating environmental dimensions. Methods included electronic searches of PubMed, Scopus, and EMBASE, as well as official health agencies' guidelines. Documents were…
Technology Assessment | Health/Medicine | Evidence Synthesis | Cost-Effectiveness Analysis | Environmental Health | Climate/Environment | Global -
ReviewPublication 2023Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: ISPOR Special Interest Group Report
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes …
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes potential approaches to mitigate them. A multidisciplinary team of biosimilar experts conducted a systematic review of literature and engaged in review rounds to identify these challenges. The article suggests that health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and conduct price comparisons for biosimilars reimbursed for the same indication as the reference biologic. In cases…
Technology Assessment | Health/Medicine | Preferences/Values | Evidence Synthesis | Policy/Regulation -
ArticlePublication 2023Evaluation of Diversity of Clinical Trials Informing Health Technology Assessments in the United States: A 5-Year Analysis of Institute for Clinical and Economic Review Assessments
The study assessed the diversity of clinical trials informing assessments by the Institute for Clinical …
The study assessed the diversity of clinical trials informing assessments by the Institute for Clinical and Economic Review (ICER) over five years (2017-2021). It conducted a cross-sectional analysis of 208 pivotal trials across 31 conditions. Findings revealed inadequate representation of racial/ethnic minorities and older adults, with Blacks/African Americans, American Indians/Alaska Natives, and Hispanics/Latinos being notably underrepresented. Whites, Asians, and Native Hawaiian/Other Pacific Islanders were adequately represented. US-based trials better represented Blacks/African Americans and Hispanics/Latinos but…
Technology Assessment | Health/Medicine | Evidence Synthesis | North America -
ArticlePublication 2023Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual
The National Institute for Health and Care Excellence (NICE) updated its Health Technology Evaluation manual …
The National Institute for Health and Care Excellence (NICE) updated its Health Technology Evaluation manual in 2022, merging processes from all 4 Health Technology Evaluation programs into a single document. Key changes include introducing a new disease severity modifier while maintaining existing methods on health inequality, discounting, unrelated healthcare costs, and value of information. Changes were categorized by importance, with most being modest updates or clarifications aligning with existing principles. The methods involved a 2-stage…
Technology Assessment | Health/Medicine | Europe